Clinical Trials Browser

Irinotecan × Gynecologic × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06459180 2026-04-17

TroFuse-020

Phase 3 Recruiting

686 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06974110 2026-04-15

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

132 enrolled

GastrointestinalGynecologic

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

442 enrolled

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 2 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Phase 1 Completed

21 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04329494 2025-12-10

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Phase 1 Recruiting

49 enrolled

GastrointestinalGynecologic

Appendiceal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT06769425 2025-06-24

HS-10502

Phase 1 Recruiting

157 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT01941316 2024-05-09

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Phase 1/2 Completed

78 enrolled 15 charts

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT04789941 2021-03-10

How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix

Phase 2 Unknown

50 enrolled

Gynecologic

Locally Advanced Cervical Carcinoma

NCT01040312 2019-05-23

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Completed

321 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Recurrence, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT00251888 2017-01-25

CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto

Phase 1 Completed

15 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT01091259 2015-11-24

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Phase 2 Completed

29 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00136955 2015-06-19

Irinotecan Study For Cervical Cancer

Phase 2 Completed

41 enrolled 9 charts

Gynecologic

Uterine Cervical Neoplasms

NCT00053833 2013-11-08

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Terminated

2 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Phase 1 Completed

41 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00003345 2013-06-21

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 2 Completed

35 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00106262 2007-04-18

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Phase 2 Terminated

38 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

TroFuse-020

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

innovaTV 301

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

HS-10502

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

SMMART Adaptive Clinical Treatment (ACT) Trial

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Irinotecan Study For Cervical Cancer

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer